We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ponatinib‐induced desquamation—Unifying eponymous terminology for a rare adverse event.
- Authors
Danish, Mohammad; Patel, Varniraj; Arava, Sudheer; Ahuja, Rhea
- Abstract
This article discusses a case of a 42-year-old man with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who developed a rare adverse event called ponatinib-induced desquamation. The patient experienced diffuse brownish hyperpigmented desquamation of the skin, primarily on the lower trunk, buttocks, and extremities. The skin lesions progressed rapidly but improved after treatment with topical emollients. Ponatinib is a tyrosine kinase inhibitor used to treat Ph+ ALL and chronic myeloid leukemia (CML), and while cutaneous adverse events are rare, they have been increasingly reported in recent years. The article suggests that these skin changes should not lead to the discontinuation of treatment for the primary malignancy.
- Subjects
CHRONIC myeloid leukemia; PITYRIASIS rubra; ICHTHYOSIS; PROTEIN-tyrosine kinase inhibitors
- Publication
Journal of the European Academy of Dermatology & Venereology, 2024, Vol 38, Issue 3, pe247
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.19553